SCHEMBL6033472

SCHEMBL6033472

Cc1c(N)nc(C(F)(F)F)nc1Cl

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.44
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
TKT P29401 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28324213 0.84 HSP90AA1 (0.35) ALDH1A1LMNAPDE4APDE4BPDE4C
SCHEMBL2743307 0.84 PDE10A (0.39) PDE10AALDH1A1KDM4E
Hydrochloric Acid SCHEMBL28122357 0.82 HSP90AA1 (0.34) ALDH1A1LMNAPDE4APDE4BPDE4C
SCHEMBL1256041 0.78 PDE10A (0.31) PDE10AALDH1A1KDM4E
SCHEMBL6401815 0.78 PDE4A (0.33) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL13522226 0.78 PDE4A (0.33) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL20013040 0.78 LMNA (0.33) ALDH1A1LMNAPDE4APDE4BPDE4C
SCHEMBL8243106 0.75 HSP90AA1 (0.31) LMNAHSP90AA1HSP90AB1KDM4ENPC1
SCHEMBL1759415 0.75 MEN1 (0.37) LMNAKDM4ENPC1ALOX15TSHR
SCHEMBL29308077 0.70 PDE10A (0.52) PDE10AALDH1A1LMNAPDE4DSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101035780-A Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain MERCK SHARP & DOHME (GB) 2007-09-12 CN disclosed
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP disclosed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US disclosed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain OPRL1, OPRK1, CNR1 PDE10A 1985/4885ALDH1A1 2879/4885LMNA 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.